184 related articles for article (PubMed ID: 23884582)
1. Clinical relevance of information in the Summaries of Product Characteristics for dose adjustment in renal impairment.
Salgado TM; Arguello B; Martinez-Martinez F; Benrimoj SI; Fernandez-Llimos F
Eur J Clin Pharmacol; 2013 Nov; 69(11):1973-9. PubMed ID: 23884582
[TBL] [Abstract][Full Text] [Related]
2. Assessing the information in the Summaries of Product Characteristics for the use of medicines in pregnancy and lactation.
Arguello B; Salgado TM; Fernandez-Llimos F
Br J Clin Pharmacol; 2015 Mar; 79(3):537-44. PubMed ID: 25224071
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of Information in Summaries of Product Characteristics (SmPCs) on the Use of a Medicine in Patients With Hepatic Impairment.
Weersink RA; Timmermans L; Monster-Simons MH; Mol PGM; Metselaar HJ; Borgsteede SD; Taxis K
Front Pharmacol; 2019; 10():1031. PubMed ID: 31607904
[No Abstract] [Full Text] [Related]
4. Information for adequate prescribing to older patients : an evaluation of the product information of 53 recently approved medicines.
Beers E; Egberts TC; Leufkens HG; Jansen PA
Drugs Aging; 2013 Apr; 30(4):255-62. PubMed ID: 23420118
[TBL] [Abstract][Full Text] [Related]
5. What should patients do if they miss a dose? A systematic review of patient information leaflets and summaries of product characteristics.
Albassam A; Hughes DA
Eur J Clin Pharmacol; 2021 Feb; 77(2):251-260. PubMed ID: 32989529
[TBL] [Abstract][Full Text] [Related]
6. The Quality and Reliability of Information in the Summaries of Product Characteristics.
Drelich E; Religioni U; Chung K; Kaźmierczak J; Blicharska E; Neumann-Podczaska A; Krysiński J; Merks P
Int J Environ Res Public Health; 2022 Feb; 19(4):. PubMed ID: 35206371
[TBL] [Abstract][Full Text] [Related]
7. Dose adjustment guidelines for medications in patients with renal impairment: how consistent are drug information sources?
Khanal A; Castelino RL; Peterson GM; Jose MD
Intern Med J; 2014 Jan; 44(1):77-85. PubMed ID: 24112311
[TBL] [Abstract][Full Text] [Related]
8. Analysis of Immunogenicity Data in the Product Information of Biological Drugs: A Need to Report Immunogenicity Data Systematically.
Borrega R; Cruz JP; Taylor P; Goncalves J
BioDrugs; 2019 Dec; 33(6):683-691. PubMed ID: 31595484
[TBL] [Abstract][Full Text] [Related]
9. Comparing cytochrome P450 pharmacogenetic information available on United States drug labels and European Union Summaries of Product Characteristics.
Reis-Pardal J; Rodrigues A; Rodrigues E; Fernandez-Llimos F
Pharmacogenomics J; 2017 Dec; 17(6):488-493. PubMed ID: 27241061
[TBL] [Abstract][Full Text] [Related]
10. Strength of evidence for labeled dosing recommendations in renal impairment.
Gagne JJ; Khan NF; Raj TS; Patel LR; Choudhry NK
Clin Trials; 2017 Apr; 14(2):219-221. PubMed ID: 27780884
[TBL] [Abstract][Full Text] [Related]
11. Natural language processing-based assessment of consistency in summaries of product characteristics of generic antimicrobials.
Shimazawa R; Kano Y; Ikeda M
Pharmacol Res Perspect; 2018 Dec; 6(6):e00435. PubMed ID: 30455958
[TBL] [Abstract][Full Text] [Related]
12. Inconsistencies of absolute drug-drug contraindication reports: Analysis of Summaries of Product Characteristics of commonly prescribed drugs.
Weisbach L; Schuster AK; Hartmann M; Dürr P; Then MI; Andrikyan W; Fromm MF; Maas R; Farker K
Br J Clin Pharmacol; 2023 Aug; 89(8):2552-2560. PubMed ID: 37002812
[TBL] [Abstract][Full Text] [Related]
13. [Antiepileptics in women of childbearing age and during pregnancy: comparison of specialized information with the current state of knowledge in Germany and Switzerland].
Winterfeld U; Gotta V; Rothuizen LE; Panchaud A; Rossetti AO; Buclin T
Nervenarzt; 2014 Jun; 85(6):738-46. PubMed ID: 24861194
[TBL] [Abstract][Full Text] [Related]
14. Shaping medicinal product information: a before and after study exploring physicians' perspectives on the summary of product characteristics.
Vromans L; Doyle G; Petak-Opel S; Rödiger A; Röttgermann M; Schlüssel E; Stetter E
BMJ Open; 2013 Aug; 3(8):e003033. PubMed ID: 23965932
[TBL] [Abstract][Full Text] [Related]
15. Renal drug dosing recommendations: evaluation of product information for brands of the same drug.
Khanal A; Peterson GM; Castelino RL; Jose MD
Intern Med J; 2014 Jun; 44(6):591-6. PubMed ID: 24946814
[TBL] [Abstract][Full Text] [Related]
16. Drug dosage adjustment in hospitalized patients with renal impairment at Tikur Anbessa specialized hospital, Addis Ababa, Ethiopia.
Getachew H; Tadesse Y; Shibeshi W
BMC Nephrol; 2015 Oct; 16():158. PubMed ID: 26446847
[TBL] [Abstract][Full Text] [Related]
17. Inconsistencies and Ambiguities in Liver-Disease-Related Contraindications-A Systematic Analysis of SmPCs/PI of Major Drug Markets.
Weisbach L; Schuster AK; Hartmann M; Fromm MF; Maas R; Farker K
J Clin Med; 2022 Mar; 11(7):. PubMed ID: 35407541
[TBL] [Abstract][Full Text] [Related]
18. [Different number of contraindications between summaries of product characteristics (SmPC) of drugs with the same active ingredients - an analysis of data from SmPCs of neuropsychiatric drugs].
Gahr M; Freudenmann RW; Connemann BJ; Schönfeldt-Lecuona C; Muche R; Hiemke C; Sillmann YM
Fortschr Neurol Psychiatr; 2020 Mar; 88(3):152-169. PubMed ID: 31127605
[TBL] [Abstract][Full Text] [Related]
19. Harmonization of summaries of product characteristics (SmPCs) of drugs with the same active ingredients: an evaluation of SmPCs of the most frequently prescribed active substances.
Gahr M; Connemann BJ; Muche R; Zeiss R; Wolf A
Eur J Clin Pharmacol; 2022 Mar; 78(3):419-434. PubMed ID: 34705065
[TBL] [Abstract][Full Text] [Related]
20. Results on patient-reported outcomes are underreported in summaries of product characteristics for new drugs.
Haag S; Junge L; Lotz F; McGauran N; Paulides M; Potthast R; Kaiser T
J Patient Rep Outcomes; 2021 Dec; 5(1):127. PubMed ID: 34874524
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
